Torque Data Shows Superior Tumor Infiltration and Killing With Deep-Primed IL-15 and Deep-Primed IL-12 Anchored to T Cells Without Systemic Toxicity

Torque, an immuno-oncology company developing Deep Primed cellular therapies with pharmacologic control to direct immune power deep within the tumor microenvironment, announced today preclinical data for the company's Deep-Primed IL-15 and Deep-Primed IL-12 programs demonstrating their activity compared to systemically administered IL-15 and IL-12.